|
- EBGLYSS® (lebrikizumab) receives positive CHMP opinion for . . . - Almirall
BARCELONA, Spain September, 15 th 2023 - Almirall S A (BME: ALM) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending the marketing authorization of EBGLYSS (lebrikizumab) for the treatment of adult and adolescent patients (12 years and older with a body weight of at least 40 kg) with
- Almirall receives European Commission approval of EBGLYSS . . .
BARCELONA, Spain November 17 th, 2023 – Almirall S A (BME: ALM), a global biopharmaceutical company focused on medical dermatology, announced today that the European Commission (EC) has approved EBGLYSS (lebrikizumab) for the treatment of adult and adolescent patients (12 years and older with a body weight of at least 40 kg) with moderate-to-severe atopic dermatitis (AD), who are
- New data show Almirall´s EBGLYSS® (lebrikizumab) provided sustained . . .
Patients taking EBGLYSS who completed any of the parent studies (ADvocate 1 and 2, ADhere, ADore, ADopt-VA) were able to enroll in ADjoin The ADhere parent study includes patients taking topical corticosteroids with EBGLYSS as a combination therapy Patients could also enroll directly into ADjoin without participating in a parent study
- Almirall receives European Commission approval of EBGLYSS (lebrikizumab . . .
EBGLYSS (lebrikizumab) for the treatment of adult and adolescent patients (12 years and older with a body weight of at least 40 kg) with moderate-to-severe atopic dermatitis (AD), who are candidates for systemic therapy Almirall will first start the commercial launch in Germany The company will continue the rollout in further European
- Almirall announces EMA acceptance for filing of Marketing Authorization . . .
BARCELONA, Spain October 28, 2022 –Almirall, S A (ALM), a global biopharmaceutical company focused on skin health, today announced that the European Medicines Agency (EMA) has accepted the filing of the Marketing Authorization Application (MAA) for lebrikizumab for the treatment of moderate to severe atopic dermatitis
- NICE recommends Ebglyss (lebrikizumab) for use in moderate . . . - Almirall
Uxbridge, UK 10 th July 2024 – Almirall S A (BME: ALM), a global biopharmaceutical company dedicated to medical dermatology, announced today that the National Institute for Health and Care Excellence (NICE) has recommended Ebglyss (lebrikizumab) for use in moderate to severe Atopic Dermatitis in the NHS England
- EBGLYSS® (lebrikizumab) is ranked as number one of the interleukin . . .
The Decision Forum has decided that lebrikizumab (EBGLYSS) should be introduced for the treatment of severe atopic dermatitis (AD) in adults and adolescents aged 12 years and older with a body weight of at least 40 kg who are eligible for systemic treatment 3 The pharmaceutical company Almirall starts the Nordic launch in Norway
- Almirall 2024 Full-Year Results | Almirall
Ebglyss® achieved 34% growth in Q4 compared to Q3, delivering a total of €33 2 MM sales in 2024, mainly in Germany The product is now available in 11 markets across Europe and continues to receive very positive feedback from dermatologists
|
|
|